News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cabrellis Pharmaceuticals Corporation Initiates Phase II Study Of Calsed(TM) In Small Cell Lung Cancer


6/5/2006 12:16:08 PM

SAN DIEGO--(BUSINESS WIRE)--June 5, 2006--Cabrellis Pharmaceuticals Corporation today announced the initiation of a phase II clinical trial of its totally synthetic, next-generation anthracycline, Calsed(TM) (amrubicin), in small cell lung cancer (SCLC). This phase II study is an open-label, randomized trial designed to assess the safety and efficacy of Calsed(TM) in reference to topotecan in the second-line treatment of patients with SCLC who previously responded to platinum-based chemotherapy. Cabrellis will conduct the study at multiple clinical centers in the United States through the US Oncology network and at the Sidney Kimmel Cancer Center of Johns Hopkins University.

Read at press release

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES